Floatz logo

Mirvetuximab Soravtansine

Recurrent Fallopian Tube Carcinoma

Ohio State University Comprehensive Cancer Centerantibody_drug_conjugatePhase 1Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

73 Active assets in the Recurrent Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
TAMOXIFEN
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Mirvetuximab Soravtansine is also rated in:

ovarian carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
fallopian tube cancerDormant
BB
Indicative ·
70 / 100
View asset →
primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →